Among the various biomarkers used to assess the effectiveness of PARP inhibitors in treating ovarian cancer, commercial genomic assays such as FoundationOne® CDx, and Myriad MyChoice® CDx are the primary ones employed in both clinical trials and clinical practice. This evidence concerns the gene PARP1 and ovarian cancer.